Search Results

1 - 3 of 3 items :

  • European Union x
  • Internal Medicine x
  • Paediatric Haematology and Oncology x
Clear All
Postępowanie u pacjentek z nowotworem mieloproliferacyjnym BCR-ABL ujemnym w ciąży

Konflikt interesu/ Conflict of interest Nie występuje. Finansowanie/ Financial support Nie występuje. Etyka/ Ethics Treści przedstawione w artykule są zgodne z zasadami Deklaracji Helsińskiej, dyrektywami EU oraz ujednoliconymi wymaganiami dla czasopism biomedycznych. Piśmiennictwo/ References [1] Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 2014;92:289–97. 24372927 10.1111/ejh.12256 Moulard O Mehta J

Open access
Implantoprosthetic rehabilitation of a patient with severe form of hemophilia B: a case report

aesthetic procedures within the field of oral surgery and implantology [ 8 , 9 ]. This greater accessibility of aesthetic procedures increases not only the comfort but also the quality of life of patients with hemophilia. The aim of this paper is to present the case of an implantoprosthetic rehabilitation performed in a patient with severe hemophilia B. The surgical procedures were performed after infusion of recombinant FIX (BAX 326) during the clinical surgery study. BAX 326 was registered in the European Union in 2014 under the trade name of Rixubis ( http

Open access
Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease

synthesized in 1869, trials for testing the safety of this drug in humans started only after a century [ 18 ]. The United States Food and Drug Administration (FDA) in 1967 approved HU for the treatment of certain solid, myeloid tumors. Further, both the US FDA and, in the European Union, the European Medicines Agency (EMA) have approved HU for the treatment of SCD in 1998 and 2007, respectively. The present review focuses on the clinical benefits of HU in SCD and enhances the current understanding of the possible mechanisms of benefit for these hemoglobinopathies. HbF

Open access